GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Return-on-Tangible-Asset

EBACU (European Biotech Acquisition) Return-on-Tangible-Asset : -3.00% (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. European Biotech Acquisition's annualized Net Income for the quarter that ended in Dec. 2022 was $-3.88 Mil. European Biotech Acquisition's average total tangible assets for the quarter that ended in Dec. 2022 was $129.23 Mil. Therefore, European Biotech Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 was -3.00%.

The historical rank and industry rank for European Biotech Acquisition's Return-on-Tangible-Asset or its related term are showing as below:

EBACU' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.27   Med: 0.71   Max: 1.15
Current: 0.27

During the past 2 years, European Biotech Acquisition's highest Return-on-Tangible-Asset was 1.15%. The lowest was 0.27%. And the median was 0.71%.

EBACU's Return-on-Tangible-Asset is not ranked
in the Diversified Financial Services industry.
Industry Median: -0.51 vs EBACU: 0.27

European Biotech Acquisition Return-on-Tangible-Asset Historical Data

The historical data trend for European Biotech Acquisition's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Return-on-Tangible-Asset Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Return-on-Tangible-Asset
1.15 0.27

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Return-on-Tangible-Asset Get a 7-Day Free Trial -1.40 4.70 0.63 -1.25 -3.00

Competitive Comparison of European Biotech Acquisition's Return-on-Tangible-Asset

For the Shell Companies subindustry, European Biotech Acquisition's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Biotech Acquisition's Return-on-Tangible-Asset Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Return-on-Tangible-Asset falls into.


;
;

European Biotech Acquisition Return-on-Tangible-Asset Calculation

European Biotech Acquisition's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=0.343/( (128.473+129.753)/ 2 )
=0.343/129.113
=0.27 %

European Biotech Acquisition's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2022 )  (Q: Sep. 2022 )(Q: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2022 )  (Q: Sep. 2022 )(Q: Dec. 2022 )
=-3.876/( (128.702+129.753)/ 2 )
=-3.876/129.2275
=-3.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2022) net income data.


European Biotech Acquisition  (NAS:EBACU) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


European Biotech Acquisition Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


European Biotech Acquisition Business Description

Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV